Madrigal Pharmaceuticals (MDGL)
Health Care · Biotechnology · NASDAQ
Madrigal Pharmaceuticals is a biopharmaceutical company commercializing Rezdiffra, the first and only FDA-approved therapy for adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.
What Madrigal Pharmaceuticals does
Madrigal Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of liver diseases. Its primary product is Rezdiffra (resmetirom), an oral, once-daily, liver-directed thyroid hormone receptor (THR)-β agonist approved for the treatment of adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.
Themes: liver disease, MASH / NASH, metabolic disorders
Fundamentals
- Price$467.54 as of 2026-10-20 close
- Market cap$10.8B as of 2026-07-27 (share count; price 2026-10-20)
- 1-year return+6.3% 2025-10-20 close $439.97 → 2026-10-20 close $467.54
- P/En/a negative earnings
- Net margin-30.1% FY2025, SEC XBRL
- ROE-47.8% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equity0.65 borrowings, leases excluded / equity — 10-Q/10-K balance sheet 2026-06-30
- Revenue growth (YoY)+432.1% FY2025, SEC XBRL
- Beta0.64 as of 2026-09-03
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How MDGL compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $364M | -$56M | -$58M | -$1.99 | $23M† | $4M† |
| Q1 FY2026 2026-03-31 | $311M | -$93M | -$94M | -$3.25 | -$167M | $4M |
| Q4 FY2025 2025-12-31 | $321M† | -$60M† | -$59M† | -$2.03† | -$133M† | -$390000† |
| Q3 FY2025 2025-09-30 | $287M | -$114M | -$114M | -$4.01 | $80M† | $857000† |
| Q2 FY2025 2025-06-30 | $213M | -$47M | -$42M | -$1.50 | -$47M† | $0† |
| Q1 FY2025 2025-03-31 | $137M | -$79M | -$73M | -$2.61 | -$89M | $0 |
| Q4 FY2024 2024-12-31 | $103M† | -$67M† | -$59M† | $2.00† | -$104M† | $195000† |
| Q3 FY2024 2024-09-30 | $62M | -$116M | -$107M | -$4.92 | -$67M† | $779000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$293M
- Short-term investments$546M
- Total debt$341M borrowings only; leases excluded
- Net debt-$498M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How Madrigal Pharmaceuticals looks technically
Madrigal Pharmaceuticals (MDGL) is trading 7.6% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 288 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 39, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 2 trading days ago. It is 24.0% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 7.6% below its 200-day average, the long-term trend line — a long-term downtrend | -7.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $512.23 | $512.23 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $506.15 | $506.15 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 35 calendar days ago — the swings before that are what the structure reading is measured on | 35 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 288 trading days ago — a "golden cross", a bullish long-term signal | 288 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with sellers in control | 42.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 39, neither overbought (above 70) nor oversold (below 30) | 39.1 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($443.48 to $510.00) — its "stochastic" reading is 36 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 36.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 26 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $615.00 | $615.00 |
|---|---|---|
| From the 52-week high | it is 24.0% below its 52-week high (its highest price of the past year) | -24.0% |
| Above the 52-week low | it is 18.8% above its 52-week low (its lowest price of the past year) | +18.8% |
| Below the 52-week high | it is 24.0% below its highest point of the past year | 24.0% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $615.00 (set on 2025-12-24) | $615.00 |
| Given back of the 52-week move | over the past year its closes ranged ($412.35 to $602.83), and it has given back well over two thirds of its rise from last year’s low — 71% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $479.02 to $485.11. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 71.0% |
| From the all-time high | it is 24.0% below its all-time high | -24.0% |
| Nearest price level | it is trading 1.4% above a support level at $461.19 — a price it turned at four times since 2025-09-08, most recently on 2026-02-05. Since 2024-10-21 it has 9 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.4% |
| All-time low | its lowest closing price on record is $5.17 (set on 2016-02-08) | $5.17 |
| Above the all-time low | it is 8939.1% above its all-time low | +8,939% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 94% of the past ~6 months) | 94th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $17.19 between its high and its low — about 3.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $17.19 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $438.04 and $532.19 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $438.04 – $485.11 – $532.19 |
| Typical daily range (% of price) | its price moves about 3.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.7% |
| Stretch from the 200-day average | it is trading 2.3 daily ranges below its 200-day average price (7.6% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.3 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.52× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.5% since the prior reading | +0.5% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
2
| Gap at the open | it opened on 2026-10-20 0.6% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.6% |
|---|---|---|
| Gap filled | a 2.2% gap up opened on 2026-08-04 has been "filled" 10 sessions ago — price traded back through the level the gap left behind, and it took 44 sessions to close | 10 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 13.0 percentage points (the stock lost 12.0% while the market gained 1.0%) | -13.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 16.4 percentage points (the stock lost 12.7% while the market gained 3.6%) | -16.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 19.8 percentage points (the stock lost 11.3% while the market gained 8.5%) | -19.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 8.3 percentage points (the stock gained 6.3% while the market gained 14.6%) | -8.3% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 8.0% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 4.6% of the share price. | -8.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 7% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $502.35 — a volume-weighted average of daily closes over 196 sessions, not a true tick-by-tick VWAP. | -6.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 7% below the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is under water. That average is $504.70 — a volume-weighted average of daily closes over 58 sessions, not a true tick-by-tick VWAP. | -7.4% |
Price levels it has turned at before
MDGL last closed at $467.54 on 2026-10-20. Since 2024-10-21 it has turned at 9 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $461.19 | Support | 1.4% below the last close | turned there four times · 2025-09-08 to 2026-02-05 |
| $447.87 | Support | 4.2% below the last close | turned there three times · 2025-10-15 to 2026-07-30 |
| $496.98 | Resistance | 6.3% above the last close | turned there five times · 2026-02-10 to 2026-08-14 |
| $508.40 | Resistance | 8.7% above the last close | turned there four times · 2026-01-28 to 2026-09-15 |
| $416.43 | Support | 10.9% below the last close | turned there four times · 2025-09-17 to 2026-03-03 |
| $535.54 | Resistance | 14.6% above the last close | turned there twice · 2025-12-18 to 2026-05-27 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.26 mean, 1=Strong Buy…5=Strong Sell) — 18 analysts
- Mean price target$685.78 range $543.00 – $962.00; median $661.50
Analyst estimates, as of 2026-10-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MDGL
- Consensus EPS estimate-$1.09 next reporting period, as of 2026-10-17
- Estimate change, 30 days$0.00 from -$1.09, on 2026-09-12, 35-day window
- Readings revised upward0% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on a single approved product (Rezdiffra) for commercial success.","Uncertainty regarding long-term market acceptance, reimbursement, and pricing by third-party payors.","Potential failure to maintain regulatory approvals or expand indications in a competitive landscape."]
What changed in the latest 10-Q
AI-assisted comparison of MDGL's 10-Q filed 2026-07-30 against the prior one filed 2026-05-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing adds MGL-0795 (formerly ARO-PNPLA3) to the list of acquired pipeline rights in the Overview section.
- Newer filing adds a description of the MAESTRO-NASH OUTCOMES trial as 'event-driven'.
- Newer filing adds a Key Developments entry: In May 2026, announced an exclusive global license agreement with Arrowhead Pharmaceuticals Inc. for ARO-PNPLA3 (now MGL-0795), described as a GalNac-conjugated siRNA design.
- Removed:
- Older filing contains a Key Developments entry: In January 2026, announced expansion of pipeline with an exclusive global license with Pfizer Inc. for ervogastat, including planned fourth quarter 2026 drug-to-drug interaction study and FDA consultation.
- Newer filing does not include the Pfizer License Agreement Key Developments entry.
- Reworded:
- The Key Developments section is truncated in the newer filing, ending mid-sentence after 'GalNac-conjugated siRNA design', while the older filing continues with the Pfizer License Agreement details.
- Notes:
- The newer filing text provided ends abruptly mid-sentence in the Key Developments section, so later portions of the newer MD&A are not available for comparison.
- The older filing text provided ends mid-sentence in the Key Developments section, so the full older Key Developments section may extend beyond what is shown.
Risk Factors
- Added:
- The newer filing (filed 2026-07-30) discloses a Rule 10b5-1 Trading Plan adopted by William Sibold, Chief Executive Officer and Director, on June 5, 2026, with a scheduled start date of 9/11/2026 and expiration date of 9/30/2027, covering a maximum of 6,706 shares.
- Removed:
- The older filing (filed 2026-05-06) disclosed a Rule 10b5-1 Trading Plan for Richard Levy, M.D., Director, modified on February 20, 2026, with a scheduled start date of 5/22/2026 and expiration date of 12/31/2026, covering a maximum of 5,682 shares.
- The older filing (filed 2026-05-06) disclosed a Rule 10b5-1 Trading Plan for David Soergel, M.D., Chief Medical Officer, adopted on March 02, 2026, with a scheduled start date of 6/1/2026 and expiration date of 12/31/2026, covering a maximum of 4,293 shares.
- The older filing (filed 2026-05-06) included a footnote explaining that David Soergel's Trading Plan provides for the sale of shares to be received upon future vesting of certain restricted stock unit awards, net of any shares sold to satisfy applicable taxes.
- Reworded:
- The newer filing (filed 2026-07-30) states the plans described were adopted during the quarter ended June 30, 2026, whereas the older filing (filed 2026-05-06) stated the quarter ended March 31, 2026.
- Notes:
- The extracted text for both filings includes content beyond the Risk Factors section (Items 2-6, exhibit list, and signatures), which is outside the scope of the Risk Factors section but was included in the provided source text.
- The core risk factor statement itself — that there have been no material changes to the risk factors from the Annual Report on Form 10-K for the year ended December 31, 2025 — is identical in both filings.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 25 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 6 days since 2026-10-16 have not been checked yet.
- Last 90 days · read to 2026-10-160 buys · 25 sells ($7M) — 2 selling insiders
- Last 180 days · read to 2026-10-160 buys · 49 sells ($12M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-11. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about MDGL's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding MDGL as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 3,506,236
- Reported value $1,882,666,179
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 1 increased, 4 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about MDGL's institutional holders → See what each manager we track holds →
Short interest (FINRA)
MDGL had 2,396,369 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
MDGL had 10.4% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.78 days to cover at the same settlement.
- Reported short interest (shares) 2,396,369
- Short interest (% of shares outstanding) 10.4%
- Prior settlement (shares) 2,254,423
- Reported change 6.3%
- Days to cover (reported) 9.78
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Viking Therapeutics
- Intercept Pharmaceuticals
- Galmed Pharmaceuticals (GLMD)
- 89bio (ETNB)
- Akero Therapeutics (AKRO)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare MDGL vs…
Frequently asked questions
What does Madrigal Pharmaceuticals (MDGL) do?
Madrigal Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of liver diseases. Its primary product is Rezdiffra (resmetirom), an oral, once-daily, liver-directed thyroid hormone receptor (THR)-β agonist approved for the treatment of adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.
What sector is Madrigal Pharmaceuticals (MDGL) in?
Madrigal Pharmaceuticals (MDGL) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are Madrigal Pharmaceuticals's (MDGL) competitors?
Notable peers of Madrigal Pharmaceuticals (MDGL) include Viking Therapeutics, Intercept Pharmaceuticals, Galmed Pharmaceuticals, 89bio and Akero Therapeutics. This peer set is informational only — not financial advice.
Is Madrigal Pharmaceuticals (MDGL) overbought or oversold right now?
Madrigal Pharmaceuticals (MDGL) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 39, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MDGL come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.